share_log

Brookline Capital Initiates Coverage On Y-mAbs Therapeutics With Buy Rating, Announces Price Target of $17

Brookline Capital Initiates Coverage On Y-mAbs Therapeutics With Buy Rating, Announces Price Target of $17

Brookline Capital開始對y-mabs therapeutics進行覆蓋,給予買入評級,並宣佈目標價爲17美元。
Benzinga ·  2024/12/05 05:16  · 評級/大行評級

Brookline Capital analyst Kemp Dolliver initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and announces Price Target of $17.

Brookline Capital 分析師Kemp Dolliver對Y-mAbs Therapeutics(納斯達克:YMAB)開始覆蓋,給予買入評級,並宣佈目標價格爲17美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論